Abstract 4367152: VANQUISH-2: Phase 3, Randomized, Double-blind, Placebo-controlled, Trial of weekly subcutaneous administration of VK2735 in Obese or Overweight Adults with Type 2 Diabetes
Year: 2025
Type: conference-abstract
Source: Circulation
Authors: Karen Modesto, Karen Chung, Summer Ji, Scott Stubbe, Karen Albers, Brian Lian
Institution: Viking Therapeutics (United States)
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4415789534